Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536976 · ClinicalTrials.gov registry record · Phase 4
Mirabegron in Parkinson Disease and Impaired Cognition
A Phase 4 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT02536976: Completed Phase 4 study, sponsored by HealthPartners Institute.
NCT02536976 is a Phase 4 study that has completed, run by HealthPartners Institute. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536976, a Phase 4 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. PD can also cause a number of non-motor symptoms that are likely to be adversely affected by the currently available anticholinergic agents. Mirabegron is the first pharmacologic treatment which may not exacerbate CI, constipation, orthostatic hypotension (OH), somnolence, and dry mouth in PD.
Primary Outcome
Change in Montreal Cognitive Assessment Total Score between week 2 and week 14. The Montreal Cognitive Assessment is a screening tool for global cognitive function with a total score ranging from 0 to 30 units on a scale, with higher score indicating better cognitive global function. Normal range is 26 thru 30.
Interventions
- DRUG Placebo
- DRUG mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 4 |
What the finished NCT02536976 record still lists
NCT02536976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02536976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02536976 about?
NCT02536976 is a clinical study titled "Mirabegron in Parkinson Disease and Impaired Cognition". There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. ...
What is the current status of trial NCT02536976?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2015-12. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02536976?
The interventions under investigation include: Placebo (DRUG), mirabegron (DRUG).
Who is sponsoring clinical trial NCT02536976?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02536976's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia